online casino game big win
PSV lose 1-0 in France against Stade Brest in the UEFA Champions League
Recent allegations of fraud against First Bank of Nigeria Limited have been refuted by the financial institution By providing over 13 million cards to customers, the bank further demonstrated its dominance in the nation According to FirstBank, it is dedicated to delivering on its brand promise of offering the gold standard of excellence and value PAY ATTENTION: Follow our WhatsApp channel to never miss out on the news that matters to you! Legit.ng journalist Zainab Iwayemi has 5-year-experience covering the Economy, Technology, and Capital Market . First Bank of Nigeria Limited has denied recent claims of fraud against the organization, calling them unfounded and devoid of proof. This followed a report of an alleged N7 billion fraud incident citing an unnamed individual with purported knowledge of the matter. The bank asked the public to completely ignore the assertions in a statement signed by Olayinka Ijabiyi, Acting Group Head, marketing and corporate communications. PAY ATTENTION: Follow us on Instagram - get the most important news directly in your favourite app! “For over 130 years, FirstBank has built an outstanding reputation for solid relationships, good corporate governance, and a strong liquidity position,” the statement read. Read also Nigeria’s newest commercial bank announces job vacancies for graduates, releases link to apply The bank also emphasized its leadership position in the country's digital payment ecosystem by issuing more than 13 million cards to consumers. Founded in 1894, First Bank of Nigeria Limited is a major player in Africa , Europe, and Asia, with subsidiaries in the Democratic Republic of the Congo, Ghana, The Gambia, Guinea, and Sierra Leone, among other nations. In order to facilitate commercial flows into Nigeria and other African nations from Asia and Europe, it also keeps a representative office in Beijing, China. FirstBank serves more than 42 million customer accounts, including digital wallets, through more than 820 corporate offices and more than 243,400 agent locations throughout 772 of Nigeria's 774 local government areas, according to the statement. With a strategic goal to deliver customer-led innovation and a mission to deliver the best financial services possible, FirstBank is committed to fulfilling its brand promise of providing the "gold standard" of value and excellence, putting its customers first in every way, the lender said. Read also Despite N250bn debt to MTN, Airtel, other telcos, banks' USSD transactions hit N2trn FirstBank remains committed to its reputation as a trustworthy and customer-focused financial organization that promotes innovation and economic progress, even in the face of the fraud accusations. First Bank holdings proposes new name Legit.ng reported that FBN Holdings Plc has announced plans to change its legal and brand name to First HoldCo Plc. In a notification signed by Adewale Arogundade, the acting secretary for the company, the bank made this announcement. The name change is one of several significant issues that the bank's shareholders will discuss during the AGM, according to the New Telegraph. PAY ATTENTION: Сheck out news that is picked exactly for YOU ➡️ find the “Recommended for you” block on the home page and enjoy! Source: Legit.ng
NAARDEN, The Netherlands and MIAMI, Dec. 10, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; "NewAmsterdam” or the "Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD”) with elevated low-density lipoprotein cholesterol ("LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the commencement of an underwritten public offering of $300.0 million of the Company's ordinary shares, nominal value €0.12 per share (the "Ordinary Shares”), and, to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase Ordinary Shares ("Pre-Funded Warrants,” and such offering, the "Offering”). All Ordinary Shares and Pre-Funded Warrants to be sold in the proposed Offering will be sold by the Company. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of Ordinary Shares, less underwriting discounts and commissions. The proposed Offering is subject to market and other conditions and there can be no assurance as to whether or when the proposed Offering may be completed, or as to the actual size or terms of the proposed Offering. Jefferies, Goldman Sachs & Co., Leerink Partners, TD Cowen, Guggenheim Securities and William Blair are acting as joint book-running managers for the proposed Offering. The proposed Offering will be made pursuant to a registration statement on Form S-3, including a base prospectus, that was initially declared effective by the U.S. Securities and Exchange Commission (the "SEC”) on July 12, 2024. The proposed Offering will be made only by means of a prospectus supplement and an accompanying prospectus, which will be filed with the SEC and will be available on the SEC's website located at www.sec.gov . A copy of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, or by telephone at (877) 821-7388, or by email at [email protected] ; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at [email protected] ; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40 th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at [email protected] ; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, or by telephone at (855) 495-9846, or by email at [email protected] ; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, or by telephone at (212) 518-9544, or by email at [email protected] ; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by telephone at (800) 621-0687, or by email at [email protected] . This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well-tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well-tolerated. Forward-Looking Statements Certain statements included in this document that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe,” "may,” "will,” "estimate,” "continue,” "anticipate,” "intend,” "expect,” "should,” "would,” "plan,” "predict,” "potential,” "seem,” "seek,” "future,” "outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the consummation of the proposed Offering as well as the timing and size of the proposed Offering and the grant to the underwriters of the option to purchase additional Ordinary Shares. These statements are based on various assumptions, whether or not identified in this document, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to the approval of the Company's product candidate and the timing of expected regulatory and business milestones, including potential commercialization; ability to negotiate definitive contractual arrangements with potential customers; the impact of competitive product candidates; ability to obtain sufficient supply of materials; global economic and political conditions, including the Russia-Ukraine and Israel-Hamas conflicts; the effects of competition on the Company's future business; and those factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as supplemented by other documents filed by the Company with the SEC. Additional risks related to the Company's business include, but are not limited to: uncertainty regarding outcomes of the Company's ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidate; risks associated with the Company's efforts to commercialize a product candidate; the Company's ability to negotiate and enter into definitive agreements on favorable terms, if at all; the impact of competing product candidates on the Company's business; intellectual property related claims; the Company's ability to attract and retain qualified personnel; and the Company's ability to continue to source the raw materials for its product candidate. If any of these risks materialize or the Company's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company's expectations, plans, or forecasts of future events and views as of the date of this document and are qualified in their entirety by reference to the cautionary statements herein. The Company anticipates that subsequent events and developments may cause the Company's assessments to change. These forward-looking statements should not be relied upon as representing the Company's assessment as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither the Company nor any of its affiliates undertakes any obligation to update these forward-looking statements, except as may be required by law. Company Contact Matthew Philippe P: 1-917-882-7512 [email protected] Media Contact Spectrum Science on behalf of NewAmsterdam Pharma Jaryd Leady P:1-856-803-7855 [email protected] Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 [email protected]Wedding couple make entry on ‘Animal’ inspired machine gun
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
Sibling seeks to rejoin family
Walker's 20 help IU Indianapolis knock off Trinity Christian 106-49
Recently, CCTV's flagship program "News Broadcast" heaped praises on Guangyu Ming Island for its significant contribution to the promotion of new industrialization in China. This recognition highlights the pivotal role that Guangyu Ming Island plays in driving forward the country's economic development and technological innovation.Arlocabtagene autoleucel is a gene-modified cell therapy commercialized by , with a leading Phase II program in Relapsed Multiple Myeloma;Refractory Multiple Myeloma. According to Globaldata, it is involved in 5 clinical trials, of which 4 are ongoing, and 1 is planned. Smarter leaders trust GlobalData The gold standard of business intelligence. The revenue for Arlocabtagene autoleucel is expected to reach an annual total of $18 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Arlocabtagene autoleucel Overview Bristol-Myers Squibb Overview (BMS) is a specialty biopharmaceutical company. It is engaged in the discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, immunology, cardiovascular, and fibrotic diseases. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. The company has an operational presence in the US, Switzerland, Puerto Rico, Ireland, and the Netherlands. The company conducts research to focus on the discovery and development of novel medicines that address diseases in areas of unmet medical need. BMS is headquartered in Princeton, New Jersey, the US. The company reported revenues of (US Dollars) US$45,006 million for the fiscal year ended December 2023 (FY2023), a decrease of 2.5% over FY2022. In FY2023, the company’s operating margin was 20.9%, compared to an operating margin of 20.9% in FY2022. In FY2023, the company recorded a net margin of 17.8%, compared to a net margin of 13.7% in FY2022. The company reported revenues of US$12,201 million for the second quarter ended June 2024, an increase of 2.8% over the previous quarter. For a complete picture of Arlocabtagene autoleucel’s valuation, From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company. The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s .
The man, whose identity has not been disclosed, embarked on the self-discipline challenges with the hopes of transforming his life and achieving personal growth. The challenges, which required strict adherence to a set of rules and routines, were designed to test the participants' willpower and determination.Inzaghi will have his work cut out for him as he tries to rally his troops and instill a sense of belief and determination in the squad. The players will need to step up and deliver a performance befitting of champions if they are to fend off the challenge posed by Lazio. The likes of Edin Dzeko, Nicolo Barella, and Milan Skriniar will need to lead by example and show their quality on the pitch.
On the other hand, Tottenham Hotspur sees Davies as an integral part of their plans for the future, with Jose Mourinho placing his faith in the young midfielder to drive the team forward. Losing Davies to Barcelona would represent a significant blow to Tottenham's ambitions, potentially forcing them to reassess their transfer strategy and identify a suitable replacement in a highly competitive market.
WEST PALM BEACH, Fla. (AP) — President-elect Donald Trump on Saturday threatened 100% tariffs against a bloc of nine nations if they act to undermine the U.S. dollar. His threat was directed at countries in the so-called BRIC alliance, which consists of Brazil, Russia, India, China, South Africa, Egypt, Ethiopia, Iran and the United Arab Emirates. Turkey, Azerbaijan and Malaysia have applied to become members and several other countries have expressed interest in joining. While the U.S. dollar is by far the most-used currency in global business and has survived past challenges to its preeminence, members of the alliance and other developing nations say they are fed up with America’s dominance of the global financial system . The dollar represents roughly 58% of the world’s foreign exchange reserves, according to the IMF and major commodities like oil are still primarily bought and sold using dollars. The dollar's dominance is threatened, however, with BRICS' growing share of GDP and the alliance's intent to trade in non-dollar currencies — a process known as de-dollarization. Trump, in a Truth Social post, said: “We require a commitment from these Countries that they will neither create a new BRICS Currency, nor back any other Currency to replace the mighty U.S. Dollar or, they will face 100% Tariffs, and should expect to say goodbye to selling into the wonderful U.S. Economy." At a summit of BRIC nations in October, Russian President Vladimir Putin accused the U.S. of “weaponizing” the dollar and described it as a “big mistake.” “It’s not us who refuse to use the dollar,” Putin said at the time. “But if they don’t let us work, what can we do? We are forced to search for alternatives.” Russia has specifically pushed for the creation of a new payment system that would offer an alternative to the global bank messaging network, SWIFT, and allow Moscow to dodge Western sanctions and trade with partners. Trump said there is "no chance" BRIC will replace the U.S. dollar in global trade and any country that tries to make that happen "should wave goodbye to America.” Research shows that the U.S. dollar's role as the primary global reserve currency is not threatened in the near future. An Atlantic Council model that assesses the dollar’s place as the primary global reserve currency states the dollar is “secure in the near and medium term” and continues to dominate other currencies. Trump's latest tariff threat comes after he threatened to slap 25% tariffs on everything imported from Mexico and Canada, and an additional 10% tax on goods from China, as a way to force the countries to do more to halt the flow of illegal immigration and drugs into the U.S. He has since held a call with Mexican President Claudia Sheinbaum, who said Thursday she is confident that a tariff war with the United States can be averted. Canadian Prime Minister Justin Trudeau returned home Saturday after meeting Trump, without assurances the president-elect will back away from threatened tariffs on Canada.In the end, Van der Saar realized that everything is connected in the world of sports, and though the outcomes may not always be as we had hoped, the journey itself is what shapes us, molds us, and ultimately defines us. Teng Haag's results may have fallen short, but his story was far from over. And in the tapestry of sports, every thread, no matter how tangled or frayed, has a part to play in the grand design of victory and defeat.
Ferencváros, a well-established club with a rich history, will undoubtedly benefit from the addition of Naby Keita to their squad. His presence is expected to bolster their midfield and provide them with a valuable asset as they strive for success in both domestic and international competitions. The club's fans are sure to be excited by the prospect of seeing such a high-caliber player in action wearing their colors.In recent days, the football world has been buzzing with speculations and rumors surrounding the future of Tottenham Hotspur's star forward, Son Heung-min. Reports surfaced claiming that Son, a beloved figure at the North London club, was on the verge of a shock move to the Turkish Super Lig. However, these rumors were swiftly shut down by his agent associated with Barcelona.
Overall, the release of version 2.5 marks a significant milestone for Yuelingxi AI, showcasing the company's dedication to pushing the boundaries of technological innovation and application capabilities. With its advanced language model, multi-modal inputs, personalized recommendations, and integration with IoT devices, Yuelingxi AI is setting new standards for AI excellence and paving the way for a more intelligent and connected future. As the world continues to embrace the potential of artificial intelligence, Yuelingxi AI stands at the forefront, leading the way towards a more innovative and intelligent future.Duke's Diaz: QB Murphy faces internal discipline for raising middle fingers in Virginia Tech winMaking spiking a specific offence is about making sure the law is up to date to deal with it as a crime, justice minister Alex Davies-Jones has said. Labour plans to make spiking a specific offence and has laid out plans for venue staff to be trained in relation to spiking, with a pilot to begin within weeks before a wider rollout next year. Ms Davies-Jones, asked about why it was worthwhile to make spiking a new offence when it is already illegal, said: “Spiking is a crime already. “A lot of people don’t realise that it is a crime already, which is part of the problem.” She said there were around 6,000 reports of spiking last year but that because it is an underreported crime, it is not clear how big of a problem it is. 'Legislation won't fix this on its own...this is about a culture shift' challenges Minister for Victims on the govt plan to change the spiking law even though it is already a criminal offence. 📺 Sky 501 — Politics Hub with Sophy Ridge (@SkyPoliticsHub) “Part of the problem we’ve got is around the data collection, so you don’t know if you’ve been spiked with a drink, a needle, a vape, for example,” she told Politics Hub on Sky News. Modernising the offence and giving police the tools to get accurate data allows a clearer picture of where, how and how often spiking is happening, she said. It is about “clarifying it, modernising it, making sure that people know exactly what this is...the law isn’t quite, it isn’t up to date. “It isn’t modern enough.” Sir Keir Starmer earlier said he hopes the change will give people “the confidence to come forward”, in a meeting of police bosses, transport figures and hospitality executives in Downing Street. Spiking will be made a criminal offence. My government was elected to take back our streets, central to this mission is making sure women and girls can feel safe at night. Perpetrators of spiking will feel the full force of the law. — Keir Starmer (@Keir_Starmer) Ms Davies-Jones and Home Secretary Yvette Cooper were among the attendees at the round-table discussion on Monday morning. Labour pledged in its manifesto to introduce a new offence for spiking, but there was no detail in the King’s Speech this year about a specific crime, though it promised to ensure an improved police response to cases. According to information published by the Metropolitan Police, spiking offences are currently covered by more than one law, but most come under the Offences Against the Person Act 1861. Sir Keir told the meeting: “There are a number of measures that we are setting out this morning – we want to talk it through with you. “The first is to make spiking a specific offence so that it counts, it’s reported.” He said that such a measure would mean that it “enables everybody to have the confidence to come forward” and also “it allows perpetrators to know that it’s a specific offence”. Detailing the training scheme, he went on: “We’re beginning the piloting of training for staff in venues.” He said the scheme would be “partly to spot what’s happening, but also to know what to do in the event that there is an incident in a venue”. “That will start in December with a pilot then it will be rolled out from March of next year,” Sir Keir added. He also said that the “final” point of discussion for the morning was “police indexing – (the) way that we count it across different police forces”. Sir Keir added: “At the moment it’s quite hard to get your arms around the pure numbers.” Plain clothes officers are being deployed in areas around bars and clubs to spot predatory behaviour. The text-to-report number, 61016, that allows women to contact British Transport Police to report harassment on the train, is due to be relaunched. Home Secretary Yvette Cooper said: “Spiking is a disturbing and serious crime which can have a damaging and long-lasting impact on victims. “That’s why today we are taking decisive action to prevent this devastating crime and to crack down on perpetrators, by introducing a new criminal offence for spiking and launching specialist training for thousands of bar staff nationwide. “People shouldn’t have to worry about the safety of their drinks on a night out. “These changes are about giving victims greater confidence to come forward, and ensuring that there is a robust response from the police whenever these appalling crimes take place.”